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INTRODUCTION
The early recognition of the serotonin (5-hydroxytryptamine; 5-HT) transporter (SERT) and the norepinephrine transporter (NET) as important targets for antidepressant drugs, fostered extensive drug discovery efforts dedicated to the design and synthesis of compounds selectively targeting SERT and/or NET (Kristensen et al., 2011) . In 1986, fluoxetine (Prozac) was approved as one of the first selective serotonin reuptake inhibitors (SSRIs) for the treatment of depression, and has since then become widely acknowledged as a breakthrough drug for depression (Wong et al., 1995; Wong et al., 2005) . Unlike the tricyclic antidepressants (TCAs), fluoxetine and other SSRI drugs are highly selective for SERT and today the SSRIs
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during the initial docking stage since this residue was blocking the S2 site. The aligning residue in SERT (Trp103) is pointing away from the S2 site in the homology model and accordingly there was no need for mutation of this residue during initial docking. The maximum number of output structures was set to 20, and the recovered binding poses were ranked according to their GScore and Emodel score. The GScore is an empirical scoring function that accounts for the interaction energy between the ligand and the protein and approximates the ligand binding free energy while the Emodel score is a combination of the GScore, the nonbonded interactions, and the internal strain of the ligand (Friesner et al., 2004) . The docking results have been divided into structural clusters based on heteroatom root-mean-square deviation (RMSD) < 2 Å in each docking. The structural clusters identified in each docking setup were further divided into global clusters.
The global clusters were defined based on an RMSD < 2.3 Å between the heteroatoms of fluoxetine.
RESULTS
Structure-activity relationship
study. Fluoxetine and nisoxetine share a substituted
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nM), whereas nisoxetine had high affinity towards NET and selectivity over SERT (4 nM versus 167 nM) ( Fig. 1 and Table 1 ). Hence, as recognized from early SAR studies, ortho substitution of the phenoxy ring appears to confer selectivity towards NET, whereas substituents in the para position induce selectivity towards SERT (Wong et al., 1975) . However, the analog with an unsubstituted phenoxy ring (compound 8)
displayed comparable affinity towards NET as nisoxetine (4 nM versus 12 nM) whereas the analog with both ortho and para substitution (compound 9) had similar binding affinity towards SERT as fluoxetine (7 nM versus 4 nM) ( Table 1) , showing that the ortho substituent is a minor determinant for selective binding in NET over SERT. In contrast, the CF 3 substituent is essential for high affinity binding in SERT and greatly reduces binding in NET (Table 1) , thus showing that this substituent is the main determinant for the distinct selectivity profiles observed for fluoxetine and nisoxetine. In agreement with previous SAR studies of fluoxetine (Horng and Wong, 1976; Wong et al., 1975) , we found that addition of an N-methyl group to fluoxetine (as in compound 7) reduced affinity towards SERT (7 nM versus 37 nM) but increased the selectivity for SERT over NET (127-fold versus 286-fold). Extending the aminoalkyl chain of fluoxetine with one methylene group (as in compound 10), had a minor effect on the affinity for SERT (7 nM versus 12 nM) but increased the selectivity over NET (127-fold versus 279-fold). The N,N-dimethyl analog of homofluoxetine (compound 11) had low activity towards both SERT and NET. The length and substitution pattern of the aminoalkyl chain on fluoxetine is thus an important determinant for binding and SERT/NET selectivity, which has also been observed for other SSRIs and TCAs (Andersen et al., 2009; Owens et al., 1997) . Fluoxetine is a racemate consisting of a 1:1 mixture of R-and S-enantiomers and, unlike other antidepressant drugs that are highly enantioselective, the two enantiomers of fluoxetine have similar binding affinities for SERT (Wong et al., 1985) . We determined the binding affinities of the R-and S-enantiomers of fluoxetine at SERT and NET, and found the two enantiomers to be 389-and 108-fold selective towards SERT over NET, respectively, thereby showing that the stereochemistry of fluoxetine is an important determinant for SERT/NET selectivity (Table 1) . In summary, our SAR analysis demonstrates that minor modifications of the chemical scaffold of fluoxetine can improve the affinity towards SERT and increase the selectivity over NET, whereas none of the compounds tested had greater affinity for NET or improved selectivity over SERT compared to nisoxetine.
This article has not been copyedited and formatted. The final version may differ from this version. Molecular docking. To create models of possible binding modes of fluoxetine in SERT and NET, we performed IFD calculations of R-and S-fluoxetine into homology models of human SERT and NET. The SERT and NET homology models were constructed using LeuT as template (Koldsø et al., 2013b) . Previous
LeuT-based models of TCA binding in human SERT (Sinning et al., 2010) have proved to be very predictive when compared with the recent structure of the eukaryotic Drosophila DAT in complex with the TCA nortriptyline (Penmatsa et al., 2013) (Supplemental Figure 1) . Specifically, we do also observe the aromatic lid (Tyr176/Phe335) to be broken in our IFD calculations of fluoxetine in human SERT, showing that the outward-occluded LeuT structure can be used as template for human SERT and still provide an inhibitorbound transporter model in an outward-open conformation. Furthermore, the overall structure of Drosophila DAT is very similar to that of LeuT, emphasizing that the LeuT-fold is conserved from prokaryotic to eukaryotic transporters, and together this substantiates the continued use of LeuT as structural template for human transporters in the study of drug binding. Initially, IFD calculations were confined to the S1 binding site of SERT and NET (denoted small IFDs). In separate runs, the entire S1/S2 region was included in the docking calculations (denoted large IFDs). The docking results have been divided into clusters based on heteroatom RMSD < 2Å, and further mapped into global clusters describing common binding modes by comparison of all clusters obtained from both small and large IFDs of both enantiomers of fluoxetine ( Fig. 2 and Table 2 ). The global clusters were defined based on RMSD < 2.3Å between the heteroatoms of fluoxetine.
Overall, we observe three global clusters of fluoxetine binding in SERT. In the most prevalent binding mode identified in SERT-Cluster 1 (containing 89% of the poses obtained) (Table 2 ), fluoxetine is located almost entirely within the central S1 site except for the CF 3 -substituted phenyl ring which protrudes out towards the S2 site (Fig. 2a ). In agreement with the similar binding affinities of R-and S-fluoxetine for SERT (Table 1) , the Gscores are also computed to be very similar for the two enantiomers. Additionally, a significant overlap between the two enantiomers in SERT-Cluster 1 is seen, where the amine of fluoxetine is anchored between Tyr95 and Asp98 on TM1, and the unsubstituted phenyl ring is located close to Ile168, Ile172 and Phe341 on TM3. Two minor global clusters of fluoxetine binding were also obtained (SERT-Cluster 2 and SERTCluster 3; 9% and 2%, respectively, of the poses obtained) ( Table 2 ). In these two clusters, fluoxetine is
1 0 exclusively located in the S2 site and the amine of the ligand is located close to Glu493 from TM10 in both clusters (Fig. 2a) .
From IFD calculations in NET, we also found three global clusters of fluoxetine binding. In the dominating binding mode (NET-Cluster 1; 63% of the poses obtained) (Table 2 ), fluoxetine is located in the S1 site below an aromatic lid (Tyr152/Phe317) (Fig. 2b) . The amine of fluoxetine is coordinated by Asp75, the CF 3 -substituted phenyl ring is located just above Phe72, and the unsubstituted phenyl ring is located close to Ile144, Val148 and Phe323. There is a significant overlap between the two enantiomers of fluoxetine in NET-Cluster 1, which is in agreement with the comparable binding affinities of the enantiomers towards NET (Table 1) . Two minor global clusters were also obtained from IFDs in NET (NET-Cluster 2 and NETCluster 3; 24% and 4%, respectively, of the poses obtained) ( Table 2 ). In NET-Cluster 2, fluoxetine is binding exclusively in the S1 site with the amine and unsubstituted phenyl ring located at similar positions as found in NET-Cluster 1, and in NET-Cluster 3 fluoxetine is binding in the S2 site in a similar pose as found in SERT-Cluster 3 (Fig. 2) . NET-Cluster 1 and NET-Cluster 2 are not similar to any of the binding modes observed for fluoxetine within the S1 site of SERT.
Experimental validation of suggested binding modes of fluoxetine in SERT.
To distinguish between the three obtained clusters of fluoxetine binding in SERT, we performed a mutational analysis of residues within 6 Å of the predicted binding modes to determine their role for fluoxetine potency. In total, 59 pointmutations across 27 different positions in the S1 and S2 sites of SERT were included in the study. Nine mutants rendered the transporter non-functional, and were not studied further (Supplemental Table 1 ). The inhibitory potency (K i ) of fluoxetine was determined at each of the 50 functional point-mutants across 24 different positions ( Fig. 3 and Supplemental Table 1 ). At five positions (Tyr95, Asp98, Ile168, Ile172, Asn177), point-mutations induced >10-fold shift in the K i -value for fluoxetine (ranging from 11-to 79-fold), suggesting these residues as key determinants for fluoxetine binding in SERT. As all five residues are all located within the S1 site of SERT, these results suggest SERT-Cluster 1 to represent the bioactive binding conformation of fluoxetine in SERT. This is in accordance with IFD calculations that also indicated fluoxetine to have the tightest binding in this cluster (Table 2) , most significantly revealed in the Emodelscores. In contrast, mutations of residues within the S2 site generally induced < 3-fold shift in fluoxetine K i 1 ( Fig. 3 and Supplemental Table 1 ), thus speaking against the binding modes predicted in SERT-Cluster 2 and SERT-Cluster 3. Notable, an ionic interaction between the amine of fluoxetine and the negatively charged side-chain of the S2 residue Glu493 on TM10 is predicted in the two minor binding clusters (Fig. 2a) .
However, removing the negatively charged side-chain by the E493A mutation had no significant effect on the potency of fluoxetine ( Fig. 3 and Supplemental Table 1 ). Furthermore, mutations of six hydrophobic residues within the S2 site (Trp103, Ile179, Trp182, Tyr232, Val236 and Val489) that seems to be important for the overall shape of the extracellular vestibule of SERT, generally only led to small shifts (< 3-fold) in fluoxetine K i ( Fig. 3 and Supplemental Table 1 Table 1 ), suggesting that TM10 residues in DAT hold a more important role for inhibitor binding compared to TM10 residues in SERT. The amine of fluoxetine was found to have a key role for high-affinity binding in SERT (Table 1 ). According to SERT-Cluster 1, the amine forms a direct interactions with Tyr95 and Asp98 on TM1, similarly to what has previously been observed for escitalopram (Koldsø et al., 2010) . Accordingly, the D98E mutation induced a 12-fold loss of potency for fluoxetine, and removal of the aromatic ring of Tyr95 (Y95A and Y95V) induced >40-fold loss of potency for fluoxetine ( Fig. 3 and Supplemental Table 1 ). Interestingly, when substituting Tyr95 for Trp (Y95W) we found a significant 8-fold gain of potency ( Fig. 3 and Supplemental Table 1 ). Since Trp is a better cation-π interaction partner compared to Tyr (Gallivan and Dougherty, 1999) , the gain of potency induced by Y95W suggests a cation-π interaction between the amine of fluoxetine and the aromatic sidechain of Tyr95. The I168F mutation induced an 11-fold gain of potency for fluoxetine ( Fig. 3 and Supplemental Table 1 ), which is likely induced by aromatic interactions between the inserted Phe and the unsubstituted phenyl ring of fluoxetine in the lower part of the S1 site (Figs. 2 and 3) . Previously, the I172M mutation has been shown to decrease fluoxetine potency (Henry et al., 2006; Sørensen et al., 2012; Thompson et al., 2011; Walline et al., 2008) . Here, we show that mutation of Ile172 to Ala, Gln and Met induced 6-to 79-fold loss of potency for fluoxetine and corroborate that Ile172 holds a key role for This article has not been copyedited and formatted. The final version may differ from this version. Table 1 ). Mutation of Asn177 on TM3 to Ala or Ser induced 7-and 25-fold loss of potency for fluoxetine, respectively. In contrast, the N177E mutation did not significantly affect fluoxetine K i ( Fig. 3 and Supplemental Table 1 ), indicating that a side-chain bearing a carbonyl group in this position is important for recognition of fluoxetine. In SERT-Cluster 1, Asn177 is located > 6.5 Å away from fluoxetine but interacts with Thr439 through an H-bond (Fig. 3) . Hence, the N177A and N177S mutations might affect fluoxetine K i in an indirect manner by modulating the overall shape of the S1 pocket by disruption of the H-bond between TM3 and TM8. The CF 3 substituent of fluoxetine was found to be a key determinant for obtaining high affinity binding in SERT (Table 1 ). In SERT-Cluster 1, the CF 3 -substituted phenyl ring is located in a hydrophobic pocket with a direct interaction between the CF 3 group and the backbone of Gly100 and aromatic π-π stacking interactions with Tyr176 ( Fig.   3 ). Backbone interactions are notoriously difficult to address by conventional mutagenesis, and we have previously shown that SERT is very sensitive to mutation of Tyr176 (Andersen et al., 2010) . Only the conservative Y176F mutation has so far been found to be functionally tolerated and had no significant effect on fluoxetine K i ( Fig. 3 and Supplemental Table 1 ). Therefore, as an alternative approach to probe specific interactions between the CF 3 substituted phenyl ring of fluoxetine and SERT, we tested nisoxetine, des-CF 3 -fluoxetine (compound 8) and 2-OCH 3 -fluoxetine (compound 9) at selected S1 mutations that induce significant changes in fluoxetine K i (Supplemental Table 2 ). Nisoxetine, 8 and 9 have different aromatic substituents compared to fluoxetine, and we thus envisioned that if the substituted phenyl ring of fluoxetine
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1 4 fold). Combining mutations within the Ile172/Ala173/Ser174 motif with A441G and L443M on TM8
induced the largest gain of nisoxetine potency, indicating that residues on TM3 and TM8 are cooperative determinants for binding of nisoxetine in SERT. The three-fold S29 mutant (SERT-S174F-A441G-L443M)
had the largest effect, and rendered SERT 24-fold more sensitive to nisoxetine compared to SERT WT (60 nM versus 1422 nM), showing that key determinants for nisoxetine selectivity are located within the S1 site of SERT.
Determination of the potency of nisoxetine at the ten functional multiple NET mutants surprisingly showed that all retained WT potency of the NET selective ligand (Fig. 4 and Supplemental Table 4 ). These data strongly suggest that, in contrast to SERT, non-conserved S1 residues do not define the inhibitory potency of nisoxetine in NET. In contrast, all multiple NET-to-SERT mutants induced a significant gain of fluoxetine potency (2-to 14-fold) ( Fig. 5 and Supplemental Table 4 ). Mutations in TM1 (F72Y and A77G), TM8
(M424L and A426G) and TM9 (Thr453) were found to be most important for improving inhibitory potency of fluoxetine in NET. Specifically, the four-fold N9 mutant (NET-A77G-M424L-A426G-T453C) induced the largest effect and rendered NET 14-fold more sensitive towards fluoxetine compared to NET WT (2993 nM versus 217 nM). Hence, non-conserved residues within the S1 site of SERT and NET are key determinants for the selectivity of fluoxetine, which are supportive of our proposed binding mode of fluoxetine (Fig. 2) .
Interchanging binding sites between SERT and NET. Interchanging non-conserved residues within the S1
site of SERT and NET modulated the potency of fluoxetine and nisoxetine. However, the selectivity was not fully reversed by any of the tested mutants. We therefore generated a series of mutant constructs in which all non-conserved residues in the S1 site and/or all non-conserved residues in the S2 site were simultaneously interchanged between SERT and NET, and thereby in principle transplanting these binding sites from SERT into NET and vice versa. Hereby, three SERT constructs containing NET S1 [SERT-(NET S1)], NET S2
[SERT-(NET S2)], and NET S1/S2 [SERT-(NET S1S2)], and two NET constructs containing SERT S1
[NET-(SERT S1)] and SERT S2 [NET-(SERT S2)] were created ( ]β-CIT, NET-(SERT S1) and NET-(SERT S1S2i),
were primarily retained within intracellular compartments (Supplemental Figure 3) . Next, we determined the binding affinities of fluoxetine and nisoxetine at the S1/S2 constructs that bind [ Table 5 ). Interestingly, the decreased binding affinity of fluoxetine in SERT-(NET S1) was reversed by simultaneous insertion of S2 site ( Fig. 5 and Supplemental Table 5 ). The binding affinity of nisoxetine was increased by 6-fold when inserting the S1 site from NET into SERT (167 nM versus 29 nM), whereas insertion of the S2 site had no significant effect on nisoxetine. Insertion of both the S1 and S2 sites from NET into SERT improved the binding affinity of nisoxetine to a similar level as observed when the S1 site was inserted alone (15 nM versus 29 nM), showing that residues located in the S1 site of SERT are key determinants for the selectivity of nisoxetine. Similar detailed analysis was not possible for NET, since only the NET-(SERT S2) construct could bind DAT and LeuBAT showed a common inhibitor binding site to be located within the central S1 site (Penmatsa et al., 2013; Wang et al., 2013) . Taken together, it seems most likely that the high-affinity binding site for nisoxetine is located within the S1 site in NET, and that the selectivity is determined by nonconserved residues lining the S2 site that nisoxetine needs to permeate in order to reach the central S1 site. In contrast, we find that the molecular determinants that underlie the lower potency of nisoxetine in SERT are primarily located among non-conserved residues within the S1 site of this transporter (Fig. 4 and Fig. 5 ).
This is in agreement with previous findings of other S1 residues in SERT that have been shown to be important for recognition of nisoxetine in SERT (Sørensen et al., 2012; Walline et al., 2008) . Hence, in contrast to fluoxetine where S1 residues in both SERT and NET control binding and selectivity ( Fig. 3 and and at multiple mutants in SERT (E) and NET (F). The inhibitory potency of fluoxetine and nisoxetine was determined in a functional uptake inhibition assay, and data represent mean ± S.E.M. from at least three independent experiments each performed in triplicate (Supplemental Table 3 and Supplemental Table 4 ).
The stippled lines indicate the potency of the inhibitors at WT transporters. Asteriks denote significantly different K i value compared with WT transporters (p < 0.01; Student's t-test). three independent experiments each performed in duplicate (Supplemental Table 5 ). The stippled lines indicate the binding affinities of fluoxetine and nisoxetine at WT transporters. Table 1 .
Binding affinity of fluoxetine and nisoxetine derivatives at SERT and NET.
The binding affinities at human SERT and NET were determined in a [
125 I]β-CIT competition binding assay, and the selectivity ratio was calculated as K i (NET WT)/K i (SERT WT).
Table 2.
Results from SERT and NET docking calculations.
The IFD setup is mentioned (either Small or Large). It is indicated if the cluster is located within the S1 or S2 site in addition to the cluster name for that setup. The number of poses in each cluster is listed with respect to the total number of poses. The average XP Gscore is listed with the standard deviation indicated in brackets. Also, the average Emodel score is listed with the standard deviation in brackets, and last it is listed in which global cluster the setup cluster belongs to. SERT WT S3 S20 S22 S27 S24 S17 S16 S29
NET WT 1 10 100 1,000 10,000
Fluoxetine Nisoxetine SERT WT S3 S20 S22 S27 S24 S17 S16 S29 NET WT F72Y  A77G V141I  I142C L146F  V148I G149A  F150S S420T  G422A M424L  A426G T453C  A477T  I481V TM1   TM8   TM3  TM3  TM1   TM8   TM3   TM1   TM6   EL4  TM3   TM1   TM6 EL4 R104 R104 S174 (S106) Figure 6 
